From Our Readers

From Our Readers

How long should a multiple myeloma patient receive lenalidomide maintenance therapy?

Here's how readers responded to a You Make the Call question about lenalidomide maintenance in a patient with multiple myeloma. Disclaimer: ASH does not recommend...

More Reasons to Become a Hematologist…

In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody...

How would you treat a patient with Wilson’s disease and neutropenia?

Here's how readers responded to a You Make the Call question about a patient with Wilson’s disease and neutropenia? Disclaimer: ASH does not recommend or endorse...

Speaking the Same Language

Dear Dr. Sekeres: I greatly enjoyed reading your clever and humorous article on gender-neutral pronouns and other language usage . I write a fair amount,...

Understanding Those Who Actually Insert Inferior Vena Cava Filters

To The Editor: As an interventional radiologist who specializes in acute and chronic deep-vein thrombosis (DVT), superficial venous disease, and complex filter removal, I applaud...

Don’t Fear the Filter

To the Editor: As an interventional radiologist who specializes in acute and chronic deep-vein thrombosis (DVT), superficial venous disease, and complex filter removal, I applaud...

Crippling Clinical Research?

I commend Dr. Sekeres for his excellent editorial (Take My Leftover Tissue, Please!), which appeared in the December 2015 issue of ASH Clinical News....

U.S. Medicine Prices: Watching from Europe with Trembling Knees

Working at the Dana-Farber Cancer Institute (then the Sidney Farber) in the Division of Tumor Immunology led by Stuart Schlossman, MD, in the early...

The Roadmap Forward in Follicular Lymphoma: Time for a Precision Approach

Over the past two decades, improved diagnostic accuracy and novel therapeutic approaches have resulted in profound improvements in overall survival in patients with follicular...

The Present and Future Multiple Myeloma Landscape

The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...
Advertisement

Current Issue

June 2018, Volume 4, Issue 7

This issue features a look at gaining oral parity for cancer medications, the unavoidable "bubbles" in which people live and work, and more.